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ABSTRACT
Background The case-crossover (CXO) and self-controlled case series (SCCS) designs are increasingly used in pharmacoepidemiology.
In both, relative risk estimates are obtained within persons, implicitly controlling for time-ﬁxed confounding variables.
Objectives To examine the consistency of relative risk estimates of hip/femur fractures (HFF) associated with the use of benzodiazepines
(BZD) across case-only designs in two databases (DBs), when a common protocol was applied.
Methods CXO and SCCS studies were conducted in BIFAP (Spain) and CPRD (UK). Exposure to BZD was divided into non-use, current,
recent and past use. For CXO, odds ratios (OR; 95%CI) of current use versus non-use/past were estimated using conditional logistic regres-
sion adjusted for co-medications (AOR). For the SCCS, conditional Poisson regression was used to estimate incidence rate ratios (IRR; 95%
CI) of current use versus non/past-use, adjusted for age. To investigate possible event-exposure dependence the relative risk in the 30 days
prior to ﬁrst BZD exposure was also evaluated.
Results In the CXO current use of BZD was associated with an increased risk of HFF in both DBs, AORBIFAP = 1.47 (1.29–1.67) and
AORCPRD = 1.55 (1.41–1.70). In the SCCS, IRRs for current exposure was 0.79 (0.72–0.86) in BIFAP and 1.21 (1.13–1.30) in CPRD.
However, when we considered separately the 30-day pre-exposure period, the IRR for current period was 1.43 (1.31–1.57) in BIFAP and
1.37 (1.27–1.47) in CPRD.
Conclusions CXO designs yielded consistent results across DBs, while initial SCCS analyses did not. Accounting for event-exposure
dependence, estimates derived from SCCS were more consistent across DBs and designs. © 2015 The Authors. Pharmacoepidemiology
and Drug Safety published by John Wiley & Sons Ltd.
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INTRODUCTION
Case-only designs overcome some key confounding
issues such as lack of information on potential
confounders, and difﬁculties in selecting appropriate
controls in numerous settings.1 One common
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characteristic of those designs is that comparisons are
within-person not between-persons, thereby control-
ling implicitly for all intrinsic factors, both measured
and unmeasured, that remain constant over the study
period. For these reasons they are increasingly being
used in pharmacoepidemiology.2
The case-crossover (CXO) method was developed
by Maclure (1991), to investigate the risk of transient
and immediate acute events.3 The particularity is that
‘controls’ come from the person-time of the case. It
uses the difference in exposure rates just before the
event (the ‘case moment’) with those at other times
(‘controls moments’) to estimate an odds ratio (OR)
of the outcome associated with exposure. It depends
on strong assumptions, being suitable for transient
exposures with short term effects.4 Hence, the inter-
mittency of drug use and the length of the exposure
time window may have an impact on the estimates
obtained.2 Also, as a conditional logistic regression
model is employed with more than one control mo-
ment, distribution of exposures must be exchangeable
between those periods to emulate a case–control
design where the order of controls is irrelevant.5
The self-controlled case series (SCCS) method was
developed by Farrington (1995) to study the associa-
tion between vaccination and adverse events.6 The
SCCS follows the cohort design approach; it is derived
from a Poisson distribution model by conditioning
on an individual’s total number of events and their
exposure history.7
The SCCS is based on several assumptions; one is
that the occurrence of the event of interest does not
inﬂuence the chance of subsequent exposure.
However, in situations where the event could temporar-
ily increase or decrease the likelihood of exposure, a
valid approach is to separately categorise a short period
of time before exposure, thereby removing this time
from the reference category (baseline or period of no
exposure) to avoid a biassed event rate in that period.
Because the designs share some features but follow
a different approach, we assessed whether they
reached similar results across electronic healthcare re-
cords databases (DBs) from the United Kingdom (UK)
and Spain following the same protocol and methodol-
ogy. As a case study we used the well-established
association8,9 of benzodiazepines and related drugs
(BZD) with hip/femur fractures (HFF). BZD are often
used intermittently, and with these case-only designs
some confounding such as frailty could be addressed.
The present research was undertaken within the
frame of the Pharmacoepidemiological Research on
Outcomes of Therapeutics by a European Consortium
(IMI-PROTECT) project (http://www.imi-protect.eu/).
PATIENTS AND METHODS
The study was performed in two primary care DBs:
The UK Clinical Practice Research Datalink (CPRD
GOLD),10 and ‘Base de datos para la Investigación
Farmacoepidemiológica en Atención Primaria’
(BIFAP) from Spain. These DBs have been described
in detail elsewhere.11 The protocol was registered in
The European Network of Centres for Pharmaco-
epidemiolgy and Pharmacovigilance, ENCePP.12 A
blinding procedure was maintained until results were
made available to the coordinating centre at Utrecht
University, the Netherlands.
Study population
The study period was considered from the 1 January
2001 until 31 December 2009. All data were used
when the practices were considered ‘Up to (research)
Standard’ (a marker of data quality). Patients who
had at least one year of registration with the general
practitioner (GP), were ≥18years old, and were
12months free of HFF were included in the study pop-
ulation. All patients were required to have a recorded
diagnosis of HFF during the study period, i.e. they
were all ‘cases’. For the SCCS, patients were required
to have 6months free of BZD prescriptions before en-
tering the study to restrict the population to new users.
This criterion was not applied for the CXO to ensure
that all case or control moments had the opportunity
to be exposed to BZD. Patients could enter at any time
they fulﬁlled the criteria above. The start date was the
date patients met the cited criteria.
Case deﬁnition
HFF was searched in the BIFAP database using the
International Classiﬁcation of Primary Care: ICPC-2,
code L75 and in CPRD using READ codes (Table
S1 online). In BIFAP, cases were identiﬁed through
free-text (in addition to codes). For that reason, a
review of all cases was carried out for validation. As
a result, similar to the companion Cohort/NCC pa-
per,13 30% of cases were excluded (of them, about
15% because of high-energy trauma, 60% because of
other fractures (i.e. pelvis), and the remaining patients
did not have a clear date of the event). Such a revision
was not feasible in the CPRD, but previous validation
conﬁrmed 91% of recorded hip fractures in the
CPRD.14 In patients with a history of past HFF, a
minimum of 12months must have elapsed between
the current episode and any previous fracture to ensure
these represented separate events.
g. requena et al.
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Exposure deﬁnition
BZD was the exposure of interest, comprising all those
classiﬁed as anxiolytics, hypnotics and related drugs in
the Anatomical Therapeutic Chemical (ATC) classiﬁ-
cation.15 (Supplementary Table S2 online). Related
drugs (Z-drugs and clomethiazole) were included in
this research because their therapeutic actions are
similar to benzodiazepines.16
Duration of each prescription was estimated based
on the prescribed amount and daily dose. The expected
duration of use was calculated following the methods
of Gardarsdottir et al.17 When a gap of more than
30days occurred between the theoretical end date of
a prescription and the date of the subsequent prescrip-
tion, exposure was considered to be discontinuous,
and a new treatment episode was considered.
The person-time of each patient was divided accord-
ing to their exposure into periods of current, recent,
past and non-use. Thus, current use was the period
from the start of a BZD prescription until 30days
after the estimated end date of the supply; recent
use was the period up to 60days after current use;
past use was the period after recent use until the
patient became exposed again or the end of follow-
up; non-use was the period between the start date
and the ﬁrst BZD prescription within the study pe-
riod. Combined non-use and past use was considered
the reference category or baseline (Figure 1). For the
SCCS, current use was further divided into ﬁve risk
time windows: 1–30, 31–60, 61–182, 183–365 and
>365days. BZD are thought to increase the risk of
fractures during the early stages of treatment,18,19
and this was taken into account when deﬁning expo-
sure time windows.
For the CXO, each case serves as its own control,
and up to four control moments were deﬁned at 91,
182, 273 and 365days prior to the HFF (case mo-
ment). This method assumes that the baseline risk for
an exposure is constant, and this assumption was
tested using up to four control periods per case,
improving the precision of the effect size, and the
efﬁciency by using the whole year prior to the event.20
For each patient, exposure at the case moment was
compared to exposure at control moments. In addition
for this design, the current use period was further
categorised as single use of anxiolytics, single use of
hypnotics and use of both.
Potential confounders
These studies are part of a common protocol where
four analytical study designs were performed to inves-
tigate the same study question (http://www.encepp.eu/
encepp/viewResource.htm?id=6179).
In the CXO, all medications mentioned in the protocol
(see Table S3 online) were considered as potential con-
founders. Indicator terms for medication use were added
to the model denoting the absence or presence of pre-
scriptions of each separate type ofmedication listed in
Table S3, within the 91days prior to the case or control
moments.
In the SCCS, age was considered as the most impor-
tant potential confounder, given its strong association
with fracture risk21 and given that many relevant
unmeasured factors are likely to be age-related
(e.g. frailty or increase in severity of underlying
diseases) as well as related to BZD pattern of use.
Analysis
Analyses in BIFAP were performed using Stata®-11;
in CPRD analyses were performed using SAS v9.2
for the CXO and Stata®-10 for the SCCS.
In the CXO, conditional logistic regression was used
to estimate the relative risk in terms of ORs with
corresponding 95% conﬁdence intervals (CI).
In the SCCS, conditional Poisson regression was
used to estimate the relative risk in terms of incidence
rate ratios (IRRs) with corresponding 95% CI.22
To examine potential event-exposure dependence, a
pre-exposure time risk window was created in the
SCCS with a length of 30days, allowing us to examine
whether an incident HFF has a short-term impact on
the likelihood of being prescribed a BZD. IRR were
estimated excluding this pre-exposure time of 30days
from the reference category in a sensitivity analysis.
Figure 1. Structure of exposure deﬁnition. The follow-up continued be-
yond the date of hip/femur fracture only for the SCCS
a comparison across case-only designs and databases
© 2015 The Authors. Pharmacoepidemiology and Drug Safety published by
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RESULTS
Case crossover. Characteristics of study populations
(BIFAP and CPRD). In BIFAP, 5412 cases were
included, with a similar mean age of 78 (±13) years
old. From these, 85% contributed four control
moments (Table 1). In CPRD, a total of 12853 cases
of HFF were included as the study population, with a
mean age (±SD) of 79 (±13) years old. From these,
88% were also registered in the DB during the four
control moments. Distribution by sex was similar in
both DBs, 78% females and 22% males. The charac-
teristics of patients are described in Table S4 online.
Effect of BZD (BIFAP and CPRD). Crude ORs (95%
CI) and adjusted OR (AORs) (95%CI) for current
use of BZD, compared to past/non-use, were similar
between DBs: OR=1.70 (1.50–1.92), AOR=1.47
(1.29–1.67) in BIFAP and OR=1.75 (1.60–1.92),
AOR=1.55 (1.41–1.70) in CPRD (Figure 2).
Effect of BZD treatment duration in CPRD. In CPRD,
although the highest relative risk was observed within
the ﬁrst 30days of treatment AOR (95%CI): 1.70
(1.49–1.94), a model accounting for duration class
did not provide a signiﬁcantly better ﬁt to the data
than one considering presence/absence of BZD expo-
sure alone (chi-square for comparison of 2log L
scores=6.82, DF=4, p=0.15) (Figure 3).
Self-controlled case series. Characteristics of study
populations (BIFAP and CPRD). In CPRD, a total of
8333 cases were included as the study population,
and a total of 4450 cases were included in BIFAP. In
Table 1. Number of cases and its control moments participating in case-crossover study in BIFAP and CPRD
Number of cases with M controls (N%) Number of cases with at least M controls (N%)
Control moments (M) CPRD BIFAP CPRD BIFAP
1 530 (4.1) 267 (4.7) 12 853 (100) 5412 (100)
2 474 (3.7) 272 (4.8) 12 323 (95.9) 5145 (95.1)
3 492 (3.8) 274 (4.8) 11 849 (92.2) 4873 (90.0)
4 11 357 (88.4) 4599 (80.6) 11 357 (88.4) 4599 (85.0)
Figure 2. Crude and co-medication adjusted risk of hip/femur fracture associated to current use of BZD. Case-crossover study
g. requena et al.
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both populations the age and gender distribution was
similar; 77% and 74% were females in BIFAP and
CPRD respectively. The mean age at ﬁrst exposure
to BZD was about 76years old in both DBs. The per-
centage of HFF occurring during the exposure to BZD
(current use) was higher in BIFAP (35%) than in
CPRD (22%), and the median duration of the observa-
tion period was shorter in BIFAP (5.4years) than in
CPRD (7.0years). Of 8333 patients exposed to BZD
in CPRD, 4790 had only a single continuous period
of BZD exposure compared to 3543 patients
(42.52%) who had intermittent BZD use. In the same
way, of 4450 patients exposed to BZD in BIFAP,
1782 had only a single continuous period of BZD
exposure compared to 2668 (59.96%) who had inter-
mittent BZD use.
Effect of BZD and related drugs. Adjusted IRR of HFF
associated with current use was 1.21 (1.13–1.30) in
CPRD and 0.79 (0.72–0.86) in BIFAP in analyses
ignoring the potential for event-exposure dependence.
In CPRD, an apparent decreasing trend of risk with
duration of treatment was observed, ranging from
1.42 (1.27–1.59) in the ﬁrst 30days of use to 0.89
(0.79–1.02) with >365days of use. In BIFAP, no
increased risk was observed in any time window cate-
gory (Table 2).
Sensitivity analysis of event-exposure dependence.
When a 30-day pre-exposure window was removed
from the reference period, an increased risk was ob-
served across all exposure period time windows. The
highest risk was exhibited by the pre-exposure time
window, with 2.52 (95%CI: 2.30–2.76) and 6.47
(95%CI: 5.91–7.09) adjusted for age, in CPRD and
BIFAP, respectively. Excluding this pre-exposure time
from the reference category we observed in BIFAP a
marked change in the magnitude of the estimates, over
all exposure time windows, reaching an IRR of 1.43
(1.31–1.57) when current use was aggregated in just
one category. Such increment was less for CPRD
varying from 1.21 (1.13–1.30) to 1.37 (1.27–1.47) in
the current use category (Table 3).
DISCUSSION
Under PROTECT’s framework of Pharmacoepidemiology
studies, four analytical designs were performed in
different databases focusing on the methodological
aspects of the studies rather than the clinical conse-
quences of the association under investigation. Two
case-only designs, studying the association of BZD
with HFF, are presented here. The results of the cohort
and nested case–control (NCC) studies for the same
association are presented elsewhere.13
CXO study. Crude and AORs were similar between
databases. Other CXO studies showed similar associ-
ations. Neutel et al.,23 for example, found a crude
OR=1.7, 95%CI: 1.0–2.9, for exposure to BZD and
Berry et al.24 found an AOR=1.66, 95%CI: 1.45–1.90
associated with the use of non-BZD hypnotics.
Concerning the effect of BZD subgroup, in both DBs
the highest risk was observed in patients taking both
anxiolytics and hypnotics, similar to the results seen
with other study designs evaluated in PROTECT.13
As falls and fractures are dose-related adverse
effects,25 the use of several drugs could be seen as
equivalent to the use of a higher dose. Alternatively,
this could partly be related to the higher severity of
the underlying conditions of these patients.
Regarding the effect of BZD treatment duration in
CPRD, although the highest relative risk was observed
within the ﬁrst 30days of treatment AOR (95%CI):
1.70 (1.49–1.94), a duration effect was not supported
Figure 3. Co-medication adjusted risk of hip/femur fracture associated to duration of current use of BZD in CPRD. Case-crossover study
a comparison across case-only designs and databases
© 2015 The Authors. Pharmacoepidemiology and Drug Safety published by
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by formal test (p=0.15). There is a lack of published
articles exploring this short-term effect of BZD and
related drugs with this design. This method assumes
immediate and transient effect as well as intermittent
exposures and the power to detect the effect of contin-
uous treatment may be limited. Possible explanations
for increasing or decreasing the risk with duration of
treatment have been discussed previously.13
In BIFAP, it was not possible to examine duration of
use in this design because data available before the
study period were insufﬁcient for assessing all dura-
tion categories.
SCCS study. An increased risk of HFF with the use of
BZD was observed in CPRD but not in any exposure
category in initial analyses after adjusting for age in
BIFAP (Table 2).
However, within these analyses, we found evidence
of a strong but temporary dependence of event and
exposure implying that some patients who sustained
a HFF were prescribed a BZD shortly after the event.
This dependence violates one of the key assumptions
of this design. Separating a 30-day period from the
reference category, the results in the SCCS were
similar to the CXO in both BIFAP and CPRD, again
suggesting an increased fracture risk associated with
exposure to BZD in all current use windows.
Gibson et al.22 also used a pre-exposure time to
assess the risk of motor vehicle crashes with BZD,
and found elevated risks (IRR=1.94, 99% CI: 1.62,
2. 32). A similar situation was observed by Lai C
et al.14 studying the risk of HFF associated with alpha
blockers using a SCCS design.
Comparison across all designs. Both traditional
(cohort and NCC) and case-only designs suggested
an increased risk of HFF associated with current use
of BZD. However, designs differed in the magnitude
of risk with traditional designs showing slightly lower
relative risks (RR) than case-only designs. Differences
observed between designs might be because of the fact
that chronic users of BZD with no unexposed observa-
tion time are excluded from the estimated RR in the
case-only designs, but can contribute in cohort and
NCC analyses. Results must be interpreted in the light
of these differences and in some instances, case-only
results may be more accurately generalised to intermit-
tent users. If chronic users of BZD had a lower risk
than short term users, explained by a better adaptation
of regular users to those drugs or by the consequence
of ‘healthy user effect’,26 traditional designs would
be expected to yield lower RR estimates than case-
only designs. Conversely, traditional designs estimate
between-person RR, while case-only estimate within-
person RR,27,28 which may not be necessarily of the
same magnitude because of unmeasured factors
difﬁcult to adjust for such as severity of underlying
diseases, or frailty. Such factors may increase the risk
of fall and fractures and may make physicians
reluctant to prescribe BZD (e.g. confounding by
contraindication). This confounding would lead to an
underestimate of the relative risk of HFF associated
with BZD use. In case-only designs, time invariant
confounding factors are implicitly controlled for by
design, although a confounding by transient changes
in other factors cannot be excluded.
The fact that the cohort/NCC analyses were re-
stricted to BZD users with a reference category of
past-use, and therefore, all patients were exposed at
least once to the drug of interest, made the comparison
between cohort members more similar than if an exter-
nal cohort of non-users had been used. In contrast, a
reference category of non-use was appropriate for the
case-only analyses, as differences between persons
are removed by design.
Results obtained with both case-only designs were
similar, although the precision of the estimates was
higher in the SCCS than in the CXO which may be
considered as potential advantage of the former.
The experience of comparing different designs using
the same source population is limited. The study of
Madigan et al.,29 part of the Observational Medical
Outcomes Partnership (OMOP) project, studied this
drug-event pair employing a SCCS and a cohort
design within the same data source, and compared
the results across ten DBs. Seven out of ten DBs found
no increased risk of HFF associated with BZD use,
when a SCCS was employed. However, this study
was not speciﬁc to BZD-HFF, and explored 53 drug-
event pairs under a surveillance perspective rather than
speciﬁcally addressing this pair in a formal hypothesis
testing study with a pair speciﬁc protocol.
There are some publications comparing designs
yielding different results, although studying different
associations.30,31 In most articles, relative risk
estimates with case-only designs were lower than
those obtained with cohort or NCC designs, with
authors generally concluding that the higher estimates
obtained using these designs may be because of
between-person confounding.
Strengths and limitations. We only had access to pre-
scribing data, rather than the precise dates on which
medication was actually taken. It is therefore possible
that exposure periods are misclassiﬁed to some extent,
with both exposed and unexposed periods affected to
a comparison across case-only designs and databases
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some degree. The effect of this would tend to bias re-
sults towards the null, and so it is possible that we
have underestimated any real effect of treatment with
BZD.A major strength of this research is the use of a
common protocol allowing the use of harmonised
methods and deﬁnitions across DBs, aiding the direct
comparison of results.
In general, case-only designs are limited by their un-
derlying assumptions. In this study, the assumption of
independence between event and exposure in the
SCCS design was not met but was subsequently
corrected for by the use of a pre-exposure risk
period.22
In our case-only two DBs have been employed with
just one drug-event association, so results might not be
extrapolated to other settings and certainly not be gen-
eralised to other drug-event pairs.
CONCLUSIONS
CXO designs yielded consistent results across DBs.
Once we accounted for the event-exposure dependence,
estimates derived from SCCS were also consistent
across DBs and across designs. Case-only designs may
offer better control for time invariant confounding
factors than traditional designs and are a useful choice
when intrinsic factors may represent relevant confound-
ing, and when the effects of transient exposures are to be
measured. Care is needed to ensure the underlying
assumptions of these designs are met and to interpret
the results obtained as they may not always generalise
to patients receiving continuous treatment with the
medication being assessed.
These studies together with the cohort and case–
control analyses have shown that performing multi-
site studies using a common protocol provides useful
comparisons across countries and across designs,
contributing to a better understanding of potential
differences between pharmacoepidemiological studies
used to assess drug safety.
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